TScan Therapeutics on Wednesday announced a $30 million deal with Swiss pharma giant Novartis (NVS) to develop therapies to treat a type of kidney cancer.
The Waltham, Mass., biopharmaceutical company is working to develop treatments that focus on T cells in the body’s immune system response. By harnessing information from T cells in recovering cancer patients, TScan aims to essentially reprogram the same cells in other patients.
